Dra. Valentina Gambardella

Investigador Emergente
Grupo de Investigación en cáncer colorrectal y nuevos desarrollos terapéuticos en tumores sólidos

Presentación

Dra. Valentina Gambardella
Investigador
Emergente
Dra. Valentina Gambardella

vgambardella@incliva.es

Publicaciones
Targeting HER2-mutant metastatic cervical cancer with neratinib: final results from the phase 2 SUMMIT basket trial. Friedman C, D’Souza A, Bello Roufai D, Tinker A, de Miguel M, Gambardella V, Goldman J, Loi S, Melisko M, Oaknin A, Spanggaard I, Shapiro G, ElNaggar A, Panni S, Ravichandran V, Frazier A, DiPrimeo D, Eli L, Solit D. Gynecologic Oncology. 2024 Jan 10:181:162-169. doi: 10.1016/j.ygyno.2023.12.004. PMID: 38211393

Altered lipid moieties and carbonyls in a wistar rat dietary model of subclinical fatty liver: potential sex-specific biomarkers of early fatty liver disease?. Martín-Grau M, Pardo-Tendero M, Casanova P, Dromant M, Marrachelli V, Morales J, Borrás C, Pisoni S, Maestrini S, Di Blasio A, Monleon D. Antioxidants. 2023 Sep 28;12(10):1808. doi: 10.3390/antiox12101808. PMID: 37891887

In the Literature: january 2023. Martin-Arana J, Gambardella V, Tarazona N, Cejalvo JM, Cervantes A. ESMO Open. 2023 Jan 3;8(1):100763. doi: 10.1016/j.esmoop.2022.100763. PMID: 36603523

In the literature: July 2023. Gambardella V, Gimeno-Valiente F, Roselló S, Cervantes A. ESMO Open. 2023 Aug;8(4):101612. doi: 10.1016/j.esmoop.2023.101612. PMID: 37467659

In the Literature: March 2023. Gambardella V, Tarazona N, Roda D, Cervantes A. ESMO Open. 2023 Apr;8(2):101203. doi: 10.1016/j.esmoop.2023.101203. PMID: 37018871

In the literature: May 2023. Gambardella V, Cejalvo J, Cervantes A. ESMO Open. 2023 May 15;8(3):101562. doi: 10.1016/j.esmoop.2023.101562. PMID: 37196398

In the literature: September 2023. Lamarca A, Moreno V, Gambardella V, Cervantes A. ESMO Open. 2023 Oct 16;8(6):102032. doi: 10.1016/j.esmoop.2023.102032. PMID: 37852035

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Jhaveri K, Eli L, Wildiers H, Hurvitz S, Guerrero-Zotano A, Unni N, Brufsky A, Park H, Waisman J, Yang E, Spanggaard I, Reid S, Burkard M, Vinayak S, Prat A, Arnedos M, Bidard F, Loi S, Crown J, Bhave M, Piha-Paul S, Suga J, Chia S, Saura C, Garcia-Saenz J, Gambardella V, de Miguel M, Gal-Yam E, Rapael A, Stemmer S, Ma C, Hanker A, Ye D, Goldman J, Bose R, Peterson L, Bell J, Frazier A, DiPrimeo D, Wong A, Arteaga C, Solit D. Annals of Oncology. 2023 Oct;34(10):885-898. doi: 10.1016/j.annonc.2023.08.003. PMID: 37597578

Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction. Papaccio F, Garcia-Mico B, Gimeno-Valiente F, Cabeza-Segura M, Gambardella V, Gutierrez-Bravo MF, Alfaro-Cervello C, Martinez-Ciarpaglini C, Rentero-Garrido P, Zuniga-Trejos S, Carbonell-Asins JA, Fleitas T, Rosello S, Huerta M, Sanchez Del Pino MM, Sabater L, Roda D, Tarazona N, Cervantes A, Castillo J. Journal of Experimental & Clinical Cancer Research. 2023 Jan 6;42(1):8. doi: 10.1186/s13046-022-02591-z. PMID: 36604765

Sequencing paired tumor DNA and white blood cells improves circulating tumor DNA tracking and detects pathogenic germline variants in localized colon cancer. Gimeno-Valiente F, Martín-Arana J, Tébar-Martínez R, Gambardella V, Martínez-Ciarpaglini C, García-Micó B, Martínez-Castedo B, Palomar B, García-Bartolomé M, Seguí V, Huerta M, Moro-Valdezate D, Pla-Martí V, Pérez-Santiago L, Roselló S, Roda D, Cervantes A, Tarazona N. ESMO Open. 2023 Nov 9;8(6):102051. doi: 10.1016/j.esmoop.2023.102051. PMID: 37951129

The prognostic potential of CDX2 in colorectal cancer: harmonizing biology and clinical practice. Badia-Ramentol J, Gimeno-Valiente F, Duréndez E, Martínez-Ciarpaglini C, Linares J, Iglesias M, Cervantes A, Calon A, Tarazona N. Cancer Treatment Reviews. 2023 Dec:121:102643. doi: 10.1016/j.ctrv.2023.102643. PMID: 37871463

In the literature: April 2022. Ciardiello D, Roda D, Gambardella V, Cervantes A. ESMO Open. 2022 Apr 23;7(3):100479. doi: 10.1016/j.esmoop.2022.100479. PMID: 35472677

In the literature: December 2021. Montagut C, Gambardella V, Cabeza-Segura M, Fleitas T, Cervantes A. ESMO Open. 2022 Feb;7(1):100352. doi: 10.1016/j.esmoop.2021.100352. PMID: 34920292

In the literature: February 2022. Gambardella V, Cejalvo JM, Gonzalez Barrallo I, Gimeno Valiente F, Cervantes A. ESMO open. 2022 Feb 23;7(2):100411. doi: 10.1016/j.esmoop.2022.100411. PMID: 35219243

In the literature: July 2022. Gambardella V, Martinelli E, Tarazona N, Cervantes A. ESMO Open. 2022 Aug;7(4):100556. doi: 10.1016/j.esmoop.2022.100556. PMID: 35961192

In the literature: November 2022. Gambardella V, Cejalvo J, Cervantes A. ESMO Open. 2022 Nov 17;7(6):100643. doi: 10.1016/j.esmoop.2022.100643. PMID: 36403559

Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma. Cabeza-Segura M, Gambardella V, Gimeno-Valiente F, Carbonell-Asins JA, Alarcon-Molero L, Gonzalez-Vilanova A, Zuniga-Trejos S, Rentero-Garrido P, Villagrasa R, Gil M, Dura A, Richart P, Alonso N, Huerta M, Rosello S, Roda D, Tarazona N, Martinez-Ciarpaglini C, Castillo J, Cervantes A, Fleitas T. British Journal of Cancer. 2022 Dec;127(12):2198-2206. doi: 10.1038/s41416-022-02005-z. PMID: 36253523

Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas. Wermke M, Felip E, Gambardella V, Kuboki Y, Morgensztern D, Hamed Z, Liu M, Studeny M, Owonikoko T. Future Oncology. 2022 Aug;18(24):2639-2649. doi: 10.2217/fon-2022-0196. PMID: 35815644

Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. Smyth EC, Gambardella V, Cervantes A, Fleitas T. Annals of Oncology. 2021 May;32(5):590-599. doi: 10.1016/j.annonc.2021.02.004. Epub 2021 Feb 17. PMID: 33609722

Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Huerta M, Rosello S, Sabater L, Ferrer A, Tarazona N, Roda D, Gambardella V, Alfaro-Cervello C, Garces-Albir M, Cervantes A, Ibarrola-Villava M. Cancers. 2021 Feb 27;13(5):994. doi: 10.3390/cancers13050994. PMID: 33673558

Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Gambardella V, Martinez-Ciarpaglini C, Fleitas T, Cervantes A. ESMO Open. 2021 Nov 6;6(6):100285. doi: 10.1016/j.esmoop.2021.100285. PMID: 34752996

Epigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer. Gimeno-Valiente F, Riffo-Campos A, Torres L, Tarazona N, Gambardella V, Cervantes A, Lopez-Rodas G, Franco L, Castillo J. Cancers. 2021 Mar 21;13(6):1433. doi: 10.3390/cancers13061433. PMID: 33801071

In the literature: April 2021. Martin-Martorell P, Gonzalez-Barrallo I, Gambardella V, Cejalvo J M, Cervantes A. ESMO open. 2021 Apr 19;6(3):100116. doi: 10.1016/j.esmoop.2021.100116. PMID: 33887688

In the literature: August 2021. Gambardella V, Alfaro-Cervello C, Cejalvo J, Tapia M, Cervantes A. ESMO Open. 2021 Aug 16;6(5):100247. doi: 10.1016/j.esmoop.2021.100247. PMID: 34411970

In the literature: December 2020. Gambardella V, Ibarrola-Villaba M, Tarazona N, Cervantes A. ESMO Open. 2021 Jan 4;6(1):100009. doi: 10.1016/j.esmoop.2020.100009. PMID: 33399075

In the literature: February 2021. Cejalvo J, Gambardella V, Fleitas T, Cervantes A. ESMO Open. 2021 Feb 24;6(2):100061. doi: 10.1016/j.esmoop.2021.100061. PMID: 33639602

In the literature: June 2021. Gambardella V, Candia L, Tapia M, Cejalvo JM, Cervantes A. ESMO open. 2021 Jun;6(3):100186. doi: 10.1016/j.esmoop.2021.100186. PMID: 34098228

Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. Gambardella V, Lombardi P, Carbonell-Asins JA, Tarazona N, Cejalvo JM, Gonzalez-Barrallo I, Martin-Arana J, Tebar-Martinez R, Viala A, Bruixola G, Hernando C, Blasco I, Papaccio F, Martinez-Ciarpaglini C, Alfaro-Cervello C, Seda-Garcia E, Blesa S, Chirivella I, Castillo J, Monton-Bueno JV, Rosello S, Huerta M, Perez-Fidalgo A, Martin-Martorell P, Insa-Molla A, Fleitas T, Rentero-Garrido P, Zuniga-Trejos S, Cervantes A, Roda D. British Journal of Cancer. 2021 Oct;125(9):1261-1269. doi: 10.1038/s41416-021-01502-x. PMID: 34493820

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers. Jhaveri K, Chang M, Juric D, Saura C, Gambardella V, Melnyk A, Patel M, Ribrag V, Ma C, Aljumaily R, Bedard P, Sachdev J, Dunn L, Won H, Bond J, Jones S, Savage H, Scaltriti M, Wilson T, Wei M, Hyman D. Clinical Cancer Research. 2021 Jan 15;27(2):447-459. doi: 10.1158/1078-0432.CCR-20-2657. PMID: 33148674

Reply to the letter to the editor: adjuvant nivolumab for the management of the pathological residual disease in esophageal or junctional tumors: a word of caution by P.K. Garg, R. Kumar and P. Dixit. Smyth EC, Gambardella V, Cervantes A, Fleitas T. Annals of Oncology. 2021 Sep;32(9):1190-1191. doi: 10.1016/j.annonc.2021.05.795. PMID: 34033882

Proyectos
Referencia: PI22/01173
Título: El papel del estrés oxidativo y la vía NRF2 en determinar resistencia a quimioinmunoterapia de primera línea en pacientes con cáncer de pulmón no microcitico avanzado KRAS mutado
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Valentina Gambardella
Duración: 2023 – 2025
Presupuesto: 111.320 €